 Abbott
Point of Care
Abbott Point of Care is the leader in critical patient blood testing
at the bedside.
The Point of Care test cartridge (microchip technology) is used
along with the handheld portable i-STAT® 1 analyzer. The advanced
technology combined with the whole-blood application at the bedside
eliminates the time associated with transport and processing of
chest pain patient's blood samples.
Emergency Department (ED) and Chest Pain Center nurses take the
single-use cartridge and analyzer to the patient bedside and add
1 drop of the patient's whole blood, receiving a lab-quality result
in just minutes. Providing the fastest cardiac marker results available
on the market today.
Faster test results provide earlier diagnosis and treatment, saving
more heart muscle. Rapid identification of those patients not having
heart attacks (the majority of chest pain patients presenting to
the ED) helps clear over crowed EDs. Additionally, the speed of
resulting helps hospitals meet the 2002' American Heart Association
/ College of Cardiology NSTEMI guidelines recommending "preferably
30- minute" turn-a-round time (TAT) for cardiac marker results.
The expanded critical care menu of Cardiac markers (TnI, CK-MB,
BNP*), Lactate (sepsis & trauma), CHEM8+, Blood gases, Electrolytes
and Glucose provides the critical care solution to clinicians so
they can make quick, accurate and informed decisions at the patient's
bedside. i-STAT® is utilized in over 1800 hospitals in America.
We improve the quality and cost of healthcare by driving real-time,
patient-side testing.
*BNP is pending FDA clearance.
 Apex Innovations
imPULSE™ ECG and Chest Pain Competency Series! Soon, Hemispheres™ Stroke Competency Series! Interactive, multi-level, web based programs for all levels of staff. Robust administrator reporting, benchmarking, testing, and CE for nurses and physicians. Extremely visual and effective, the courses within imPULSE™ include Heart Basics, Obtaining ECGs and Troubleshooting, Heart Rhythms and Interventions, 12 Lead ECGs, Acute Coronary Syndrome, Advanced and Special Situations and a Reference Library. imPULSE™ is the only program to meet all of the key educational elements required for Chest Pain Center accreditation. 3D MI Rule® Visions, clinically proven to increase understanding of 12 lead ECGs and includes updated AHA/ACC guidelines for UA / NSTEMI / STEMI, and other important references! www.apexinnovations.com 866-294-4599
 AstraZeneca
AstraZeneca is a major international healthcare business engaged in the research, development, manufacture and marketing of prescription pharmaceuticals and the supply of healthcare services. It is one of the world's leading pharmaceutical companies with healthcare sales of $26.47 billion and leading positions in sales of gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infection products. AstraZeneca is listed in the Dow Jones Sustainability Index (Global) as well as the FTSE4Good Index.
In the United States, AstraZeneca is a $12.44 billion healthcare business with more than 12,000 employees. For nearly three decades, AstraZeneca has offered drug assistance programs side by side with its medicines, and over the past five years, has provided over $3 billion in savings to more than 1 million patients throughout the US and Puerto Rico. AstraZeneca has been named one of the “100 Best Companies for Working Mothers” by Working Mother magazine and is the only large pharmaceutical company named to FORTUNE magazine’s 2007 list of “100 Best Companies to Work For.” In 2006, for the fifth consecutive year, Science magazine named AstraZeneca a “Top Employer” on its ranking of the world’s most respected biopharmaceutical employers. For more information about AstraZeneca, please visit: www.astrazeneca-us.com
 Biosite
Incorporated
A
leader in the drive to advance diagnosis, Biosite Incorporated is
a research-based company dedicated to the discovery and development
of novel protein-based diagnostic tests that help clinicians rapidly
diagnose acute conditions such as heart failure, chest pain/ACS,
drug overdose and trauma. Biosite's Triage brand rapid tests include
the Triage Cardiac Panel, the Triage BNP Test, the Triage Cardio
ProfilER, the Triage TOX Drug Screen, the Triage Drugs of Abuse
Panels, the Triage C.difficile Panel and the Triage Parasite Panel,
and combined, these are used in approximately 50 percent of U.S.
hospitals and in 40 international markets. Biosite currently has
a diagnostic test for acute stroke in development.
 Dade
Behring
With
2004 revenues of nearly $1.6 billion, Dade Behring is the world's
largest company dedicated solely to clinical diagnostics. The diagnostics
industry plays a key role in saving lives and is a critical part
of the health care continuum. Dade Behring offers products and systems
designed to meet the day-to-day needs of laboratories. The company's
single focus on the clinical lab offers its customers an unparalleled
commitment to responsive service, innovative products, consistent
quality, and lasting relationships of trust. Dade Behring is headquartered
in Deerfield, Illinois, and has operations in 43 countries, employs
approximately 6,000 people and serves more than 24,000 customers
worldwide.
The
businesses from which Dade Behring was formed have been innovators
in clinical diagnostics for more than a century. Dade Behring was
created in 1997 through the merger of Dade International and the
Behring Diagnostics unit of Hoechst AG. Earlier, these companies
had combined the diagnostics businesses of the DuPont Company, Syva
Company and Baxter Healthcare. Now, Dade Behring ranks as the sixth
largest diagnostics company in the world.
 Molecular
Insight Pharmaceuticals
Molecular Insight Pharmaceuticals is focused on becoming a leader
in the rapidly emerging field of molecular medicine through the
development and commercialization of innovative pharmaceuticals
that utilize highly specific targeting technologies designed to
meaningfully improve patient diagnosis, treatment and management.
Molecular Insight's lead product candidate, Zemiva™ (iodofilic
acid l 123), has completed Phase 2b clinical development for use
in triaging emergency room patients with suspected acute coronary
syndrome, a situation that results in over six million emergency
room visits annually in the United States. The company's first radiotherapeutic
candidate, Ultratrace™ MIBG, for the evaluation and treatment
of neuroendocrine tumors, is in late preclinical development. Molecular
Insight's pipeline leverages proprietary technologies for targeting,
visualizing, treating, and monitoring desease in cardiology, oncology
and neurology. Molecular Insight Pharmaceuticals is based in Cambridge,
Massachusetts. Its web site address is: www.molecularinsight.com
PDL BioPharma, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative therapies for severe or life-threatening illnesses. Commercially focused in the acute-care hospital setting, PDL markets and sells its portfolio of leading products in the United States and Canada. A pioneer of antibody humanization technology, PDL promotes this technology through licensing agreements and clinical development of its own diverse pipeline of investigational compounds. PDL's research platform centers on the discovery and development of antibodies to treat cancer and autoimmune diseases. For more information, please visit www.pdl.com.
Sanofi-aventis
Sanofi-aventis is the world’s third largest pharmaceutical company, ranking number one in Europe. Backed by a world-class R&D organization, sanofi-aventis is developing leading positions in seven major therapeutic areas: cardiovascular, thrombosis, oncology, metabolic diseases, central nervous system, internal medicine, and vaccines. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).
 Scios
Inc.
Scios Inc. is a leader in heart failure treatment and committed to bringing new therapeutics for cardiovascular disease, inflammatory disease and cancer to patients with unmet medical needs.
 Sepracor
Inc.
Sepracor Inc. is a research-based pharmaceutical company dedicated
to treating and preventing human disease by discovering, developing,
and commercializing innovative pharmaceutical products that are
directed toward serving unmet medical needs. Our drug development
program has yielded a portfolio of pharmaceutical products and candidates
with a focus on the treatment of respiratory and central nervous
system disorders. Our commercialization efforts are carried out
by our U.S.-based, primary care and specialty-oriented sales force.
Sepracor commercializes three proprietary products, LUNESTA™
(eszopiclone), XOPENEX® (levalbuterol HCl) Inhalation Solution
and XOPENEX HFA™ (levalbuterol tartrate) Inhalation Aerosol,
a hydrofluoroalkane (HFA) metered-dose inhaler (MDI). Sepracor’s
out-licensing agreements include: Schering-Plough for CLARINEX®
(desloratadine); sanofi-aventis for ALLEGRA® (fexofenadine HCl);
and UCB Pharma for XYZAL®/XUSAL™ (levocetirizine). Sepracor’s
corporate headquarters are located in Marlborough, Massachusetts.
|
